Showing results (1011-1020 of 1,020) with videos related to

Sort By:
Pageof 102
You have reached the last page of results.This site can display upto 1,020 results.
Cancer Research Communications|October 1, 2026
Lymph node lymphatic PD-L1 regulates tumor-infiltrating T cells in immune checkpoint-sensitive melanomaEmma Reynaud, Sonya Belherazem, Shruthi Hemanna, et al.
Cancer Research Communications|October 12, 2026
Elucidating the Gene Expression Signature of Rosai-Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes InitiativeSheren Younes, Fadzai Chinyengetere, Veronica Russell, et al.
Cancer Research Communications|October 12, 2026
Androgen-mediated T cell suppression drives sex bias in head and neck squamous cell carcinomaQuinn Hopen, Samantha Antol, Carly J Amato, et al.
Cancer Research Communications|September 23, 2026
Dissociated response to immune checkpoint inhibition in head and neck squamous cell carcinoma is common and exhibits distinct clinical outcomesAlice N Weaver, Stephen B Keysar, Aarti Dureja, et al.
Cancer Research Communications|September 23, 2026
Gustave Roussy Immune (GRIm) score validation in patients treated with Bispecific CD3 T-cell engagers in phase I clinical trialsNoé Herbel, Clara Helal, Kaïssa Ouali, et al.
Cancer Research Communications|October 5, 2026
Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: a Multicenter Prospective Observational Study (COSMOS-MEL01)Yoshiaki Nakamura, Kenjiro Namikawa, Dai Ogata, et al.
Cancer Research Communications|October 5, 2026
HIV and Antiretroviral Therapy Influence Tumor Microenvironment Architecture, Subclonal Evolution, and Immune Evasion Strategies in Diffuse Large B-Cell LymphomaJenny Coelho, Sophia M Roush, Samantha Beck, et al.
Cancer Research Communications|October 19, 2026
Biomarker Modulation by Aspirin and Metformin for Colorectal Cancer Prevention: Results from the ASAMET Randomized Phase II TrialIrene M Briata, Alessio Carbone, Sebastian Foersch, et al.
Cancer Research Communications|October 19, 2026
Paxalisib with Trastuzumab for HER2-Positive Metastatic Breast Cancer with Active Brain Metastases: A Phase II Trial with Integrated Plasma and CSF ctDNA AnalysesElia Segui, Jorge Gomez Tejeda Zañudo, Noah Graham, et al.
Cancer Research Communications|October 23, 2026
Cancer cell CD73 loss promotes a dual inflammatory and immunosuppressive microenvironment in endometrial carcinomaHannah N Lee, Xingyuan Zhang, Suzanne M Crumley, et al.
Pageof 102